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Abstract Intheearlydays,airplaneswereputtogetherwith
parts designed for other purposes (bicycles, farm equipment,
textiles, automotive equipment, etc.). They were then ﬂown
by their brave designers to see if the design would work—
often with disastrous results. Today, airplanes, helicopters,
missiles, and rockets are designed in computers in a process
that involves iterating through enormous numbers of designs
before anything is made. Until very recently, novel drug-like
molecules were nearly always made ﬁrst like early airplanes,
then tested to see if they were any good (although usually not
on the brave scientists who created them!). The resulting
extremelyhighfailurerateislegendary.Thisarticledescribes
some of the evolution of computer-based design in the aero-
spaceindustryandcomparesitwiththeprogressmadetodate
in computer-aided drug design. Software development for
pharmaceutical research has been largely entrepreneurial,
with only relatively limited support from government and
industryend-userorganizations.Thepharmaceuticalindustry
isstillabout30 yearsbehindaerospaceandotherindustriesin
fully recognizing the value of simulation and modeling and
funding the development of the tools needed to catch up.
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Forty years ago this year, fresh out of graduate school, I
worked in the aerospace industry as a young engineer
(actually, ‘‘rocket scientist’’). My ﬁrst aerospace job in 1971
was developing a computer program to simulate and opti-
mize the ascent trajectoryofthe space shuttle togetthe most
payload into an orbit 150 nautical miles above the equator.
Theprogramconsistedofsixboxesofpunchcards(2,000per
box) written in Fortran 4. The simulation included a rotating
earth, modeled as an oblate spheroid (to calculate how
gravity changes with both altitude and latitude), a NASA
standard atmosphere model with the ability to simulate hot
and cold days as well as wind proﬁles at different altitudes,
andthenumericalsolutionofallofthedifferentialequations
necessary to track the latitude, longitude, and altitude of the
space shuttle over the rotating earth during ﬂight.
Our primary computer was a Univac 1108 that ﬁlled a
specially air-conditioned room occupying probably 1,000
square feet. A single run of the program simulated hun-
dreds of trajectories as it worked to optimize the steering
commands in pitch and yaw. Different ascent trajectories
result in different complex interplays of thrust, drag, and
gravity as the vehicle moved from the dense air at sea level
to the near-vacuum of space, turning ﬁrst southward toward
the equator, then back to the east to end up in an equatorial
orbit, all the while getting lighter as the fuel is expended,
with a moving center of gravity, and quickly achieving
supersonic ﬂight where a complex pattern of shock waves
forms around the orbiter, external tank, and booster rock-
ets. The objective of optimizing the steering commands is
to minimize the losses due to aerodynamic drag and gravity
during the climb, so that fuel is used most efﬁciently to put
as many pounds of payload into orbit as possible. Finding
an optimized steering solution for a particular set of system
weights and environmental conditions (hot day, cold day,
winds, etc.) required 12–14 h of CPU time. My laptop
today would execute the same equations and achieve an
optimized solution in a fraction of a minute. But consider
this—NASA was funding this simulation and modeling
effort 10 years before the ﬁrst launch, and even before the
vehicle design was ﬁnalized.
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resulted in accidentally discovering the shuttle’s signature
roll maneuver—the program told us to roll it over on its
back and ﬂy upside down and we’d pick up about 8,000
pounds of free payload! A combination of more efﬁcient
aerodynamics and the required thrust vector angles for the
main (liquid hydrogen/liquid oxygen) engines to balance
the moments around the moving center-of-gravity provided
the increase. Ask many astronauts today why it ﬂies upside
down and most can’t tell you. By developing this complex
(for its day) simulation, we assembled many bits of known
information and theory to discover something that was
unknown prior to having the simulation capability, and that
turned out to be extremely valuable.
We used complex computer simulations in all of my
aerospace jobs in the 1970s and 1980s, both to gain insight
into our systems and to optimize their designs. They saved
immeasurable time and money as we were able to try and
fail an enormous variety of ideas quickly with no actual
losses by iterating through countless virtual design options
to ﬁnd an optimal solution. That was 30–40 years ago!
Today, aerospace, automotive, electronics, and other
industries routinely incorporate far greater detail into sim-
ulations and run them much faster to answer questions like:
how much load a metal or composite part can take before
bending or breaking, how aerodynamic surfaces might
ﬂutter at certain speeds and angles of attack, how the
stresses in a very hot jet engine turbine blade will be
affected as a ﬁghter jet does a high-G maneuver, and many
more complex behaviors. Numerical methods have evolved
to speed up calculations along with the speed and memory
improvements in computer hardware. In fact, today we even
have ‘‘electronic wind tunnels’’ that can provide an accurate
estimate of the aerodynamic forces on complex vehicles
without the need to build scale models and test them in real
wind tunnels. The solution of the Navier–Stokes equations
for ﬂuid ﬂow was once considered so complex that even
supercomputers were not expected to solve them with a ﬁne
enough grid to calculate such forces accurately.
This Computational Fluid Dynamics (CFD) computer-generated
image shows a model of the space shuttle. CFD has taken the place
of wind tunnels for many evaluations of aircraft and, as computing
power increases and computer models become more sophisticated,
CFD will largely replace wind tunnels. Image credit: NASA.
Many major aerospace projects require a decade or more
of R&D along with over a billion dollars in investment to
get a single new product to market. Sound familiar? Most
of these projects will involve hundreds of millions of dol-
lars spent on simulation and modeling. That part does not
sound familiar to pharmaceutical scientists. Yet the risks
and costs associated with pharmaceutical R&D are on a
level not so different from large development projects in
aerospace, automotive, and other industries.
Why has pharmaceutical research and development
lagged so far behind other industries in the development
and application of simulation and modeling for research
and development? I believe there are at least three main
factors:
1. Aerospace simulation and modeling software involves
complex physics and chemistry. Pharmaceutical sci-
ence adds biology to these, which increases variability
and complexity.
2. Aerospace simulation and modeling generally uses
well-established inputs that are measured with rela-
tively high accuracy and relatively small variance. So
even though many inputs are required for a simulation
as complex as the launch of a Space Shuttle to orbit, the
inputs for the vehicle itself are well-known. The reason
they are well-known is because the industry goes to the
time and expense to perform experiments to get
parameter values whose sole purpose is to be used as
inputs to simulations. For example, the payoff from
exhaustive (and expensive) wind tunnel experiments at
a wide variety of altitudes (ambient pressures), angles
of attack, and vehicle conﬁgurations (position of
landing gear and ﬂaps, etc.) is that they make possible
accurate simulation of the entire ﬂight envelope for a
new vehicle. As opposed to the vehicle inputs, those for
the environment (atmosphere) are less predictable, but
like population virtual trials, those conditions are
handled with Monte Carlo simulations that vary the
conditions over the expected range of winds at various
altitudes, temperatures, and air densities. The pharma-
ceutical industry largely does not yet recognize that
taking data with simulation and modeling in mind could
radically change the failure rate that plagues drug
discovery and development. Pharmaceutical simulation
and modeling typically has to use inputs that have been
measured in a way that sacriﬁces accuracy for high-
throughput go/no-go decisions.
3. Aerospace researchers are primarily engineers, who
are trained to be generalists, integrating a variety of
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analysis, ﬂight dynamics, heat transfer, thermodynam-
ics, internal ballistics, solution of differential equations,
computer programming, and other disciplines all enter
into a typical rocket motor simulation of the 1970’s).
Pharmaceutical researchers are primarily scientists who
are trained in narrow silos to become specialists rather
than generalists. It takes good generalists to get
maximum beneﬁt from system simulations that incor-
porate diverse areas of science including, for example,
physiologies of various animals and human popula-
tions, formulation issues, in vitro—in vivo correlation
methods, metabolism, transporters, solubility effects,
fasted and fed state differences, numerical optimiza-
tion, and machine learning methods.
4. The knowledge base for many aspects of physics and
chemistry provides a foundation upon which to build
good mechanistic models of the systems under study.
The knowledge base for pharmaceutical research is
growing at an encouraging rate, yet today there remain
many kinds of information that are not yet available for
certain kinds of simulation and modeling. An example
is the level of expression of various transporters in
different tissues in different species, and their variances
in populations. Fortunately, progress has been made
over recent decades and a very useful (if yet far from
complete) knowledge base now exists upon which to
build useful simulation and modeling tools.
To say that pharmaceutical science is too difﬁcult or
lacks a sufﬁcient knowledge base to build good mecha-
nistic models was an argument 20–30 years ago—it is no
longer a valid argument today. George Box is often quoted,
‘‘All models are wrong, some are useful’’. Current simu-
lation and modeling tools for drug discovery and devel-
opment are very useful, and improvements are coming
rapidly. Yet their adoption has taken 10–15 years to reach
current usage levels, which remain well below where they
are in other industries.
There is no greater productivity tool than software. I’ll
say that again—there is no greater productivity tool than
software! Don’t believe it? Try working without your word
processor, databases, spreadsheets, presentation software,
e-mail, Internet, and so on. We use (and usually take for
granted until we have a glitch) software in more ways than
we realize. Managers have no reservations about purchas-
ing software for such uses. Fortunately, these types of
software are developed for millions of users, providing an
economy of scale that supports sophisticated software at
prices that even retirees can afford.
The development costs for sophisticated simulation and
modeling software are very high—in the tens millions of
dollarsforthemoresophisticatedprograms.Likesimulation
and modeling software used in aerospace and other indus-
tries, thenumberofusers isrelativelysmall, making the cost
per user much higher than for commercial software sold in
huge quantities. Specialized teams of scientist/programmers
(or separate scientists and programmers—but that’s a sub-
ject for another article) spend many person-years bringing
such software to commercial standards and providing
ongoing support and enhancements. Many senior pharma-
ceutical R&D managers grew up without exposure to the
beneﬁts of such tools, resulting in skepticism and difﬁculty
recognizing the beneﬁts of the insight they provide.
Many pharmaceutical scientists are skeptical of com-
puter software that combines mathematical relationships in
ways that are so complex that no human can grasp the full
interplay of the equations and logic involved. Even the
simplest mechanistic simulation of oral absorption and
pharmacokinetics can involve hundreds of interacting dif-
ferential equations. Aerospace researchers expect this and
don’t expect to be able to intuit results by examining a few
key inputs. I have listened to numerous presentations at
scientiﬁc meetings where speakers drew sweeping con-
clusions from a few parameters like polar surface area,
logP, and molecular weight, with heads in the audience
nodding in agreement with the speaker. Sorry, folks, but
it’s just not that simple! If it was, we’d be releasing new
drugs every week!
Correlating molecular structures with a wide variety of
activity and ADMET properties remains a particular chal-
lenge. If the often-heard number of potential drug-like
molecules is truly on the order of 10
62, then clearly there is
no hope for humankind to ever investigate all of them. In
fact, the vast number of possible interactions among atoms
within molecules and between molecules and their envi-
ronments make it highly unlikely that humankind will
derive purely mechanistic (and quantum) methods for
predicting most properties from structure with experimen-
tal accuracy in the foreseeable future. ‘‘Activity cliffs’’ or
‘‘property cliffs’’ (minor changes in molecular structure
that result in large changes in activity or other properties)
are seen regularly that defy similarity (Tanimoto, nearest
neighbor) rules and chemists’ intuition. Changing a single
atom in a molecule will affect every property of that
molecule—not only afﬁnity for the target, but all of its
physicochemical and biopharmaceutical properties,
metabolism, potential toxicities, etc. We simply don’t have
a large enough knowledge base from which to build
ab initio models for every property of concern, so empirical
methods are going to be around for a very, very long time
in this part of pharmaceutical science. So what are we to do
to get out of the ‘‘make and test’’ mode and go more into
‘‘design, then make’’ mode that other industries enjoy?
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has enabled the evolution of powerful machine learning
methodologies. Some of these methods are so complex that
they defy direct human comprehension, but they have
proved to provide the most accurate structure–property
predictions available to date. Pharmaceutical scientists
need to accept that there are tools that exceed the ability of
humans to grasp in simple terms. In the aerospace industry,
the use of computer numerical control (CNC) machining
has enabled the manufacture of complex shapes from
blocks of metal that would have been extremely difﬁcult to
machine by hand using the methods of a few decades ago.
The use of composite materials has reduced weight while
increasing strength, but the new science required to model
such structures (which behave quite differently than met-
als) had to be developed.
In 1982, I developed a computer program to calculate the
optimum ﬁlament winding angles for the ﬁrst graphite/
epoxy rocket motor. We knew enough from experiments to
know how the composite material would behave in terms of
both longitudinal (the length of the motor) and hoop (in the
direction of the diameter of the motor) stresses. Making a
rocketmotorfromalongﬁlamentofcarbonﬁberandapotof
epoxy had not been done before. The ﬁber has to be con-
tinuous from one end of the motor to the other to support the
longitudinal stresses that try to stretch the motor when the
pressure inside goes from zero to thousands of pounds per
square inch in a fraction of a second. The ﬁber, wetted with
epoxy,iswoundoveramandrel,aroundeachendandreturns
in barber-pole fashion, but at a relatively shallow angle.
Afterthelongitudinalwindsarecompleted,asecondprocess
begins with a ﬁlament wound around the motor diameter in
consecutive circles (hoops) to give it the strength it needs in
the hoop direction. After all the windings are completed and
after a curing process in an autoclave, the mandrel is
removed and the case is ready for loading with propellant.
We did exactly that, added the nozzle, and ﬁred the motor—
the world’s ﬁrst graphite/epoxy rocket motor, designed by a
computer program, was a complete success.
We have to accept that we can learn things we don’t
know from things that we know—i.e., we may know a
large number of individual facts and measurements (and
molecular and atomic descriptors), but we don’t know how
they all interact. The pharmaceutical industry spends mil-
lions of dollars ﬁlling databases, spreadsheets, and reports
with bits of diverse data, but with rare exceptions, no one
can look through all of the data on a compound and tell you
how it’s going to behave in vivo. Only through highly
sophisticated simulation and modeling do we have a
chance at gaining insight into how all of the diverse
properties play together.
The state-of-the-art today for predicting most properties
from structure yields root-mean-square errors on the order
of 0.3–0.5 log units, or about two-to three-fold. Aerospace
designers would have a very tough time with such high
uncertainty, since the safety factor added to some calcu-
lations is often as low as 1.4! Imagine if a part needs to
carry a stress of 1,000 pounds, and is designed stronger to
fail at an estimated 1,400 pounds in order to provide that
safety factor of 1.4. If the actual error in the stress capa-
bility was 0.3 log units lower than expected, then the
failure would occur at 700 pounds when it needed to
handle 1,000, and disaster would follow. Fortunately, we
don’t have to deal with such tight safety factors for most
drugs.
Every drug that fails in a clinical trial or after it
reaches the market due to some adverse effect was ‘‘bad’’
from the day it was ﬁrst drawn by the chemist. State-of-
the-art in silico structure–property prediction tools are not
yet able to predict every possible toxicity for new
molecular structures, but they are able to predict many of
them with good enough accuracy to eliminate many poor
molecules prior to synthesis. This process can be done on
large chemical libraries in very little time. Why would
anyone design, synthesize, and test molecules that are
clearly problematic, when so many others are available
that can also hit the target? It would be like aerospace
companies making and testing every possible rocket
motor design rather than running the simulations that
would have told them ahead of time that disaster or
failure to meet performance speciﬁcations was inevitable
for most of them.
The pharmaceutical industry is undergoing an awak-
ening with respect to simulation and modeling tools. You
can see it in the titles of presentations and posters at
major scientiﬁc meetings, and in the number of smaller
meetings with a strong focus in these areas. I predict that
the day will come (probably not in my lifetime, but it will
come) when pharmaceutical research and development
will be so heavily driven by simulation and modeling
tools that many fewer failures will occur in clinical and
preclinical phases. Discovery efforts guided by de novo
design tools available now offer the promise of more
rapid discovery of good lead compounds and elimination
of the majority of ‘‘losers’’ without the need to make and
test them. Exploration of very large compound libraries
automatically is already underway in a few organizations.
I believe that many others will come to realize that
simulation and modeling tools, properly applied, repay
their costs many times over. A commitment to the
investment in developing skilled generalists and support-
ing the development of the tools themselves has been
made in relatively few organizations to date. Hopefully,
the awakening we’ve seen in recent years will continue to
grow and senior management will recognize that simu-
lation and modeling does not cost money—it saves
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123considerable time and money. For an industry that
requires a long-term view of research and development,
recognizing the value of predictive tools would seem to
be a no-brainer.
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